Nomiyama Takashi

ノミヤマタカシ | Nomiyama Takashi

Affiliation and department：

Research field (3)： Metabolism and endocrinology , Metabolism and endocrinology , Cardiology

Research keywords (4)： Vascular Biology , Endocrinology , Metabolism , Diabetes

Research theme for competitive and other funds (4)：

2018 - 2023 GLP-1 receptor expression in cancer cells
2015 - 2018 Comprehensive studies of androgen and SARM as a background of onset or treatment of life-related diseases
2011 - 2014 Research on a novel selective androgen receptor modulator, S42 for the development of life-related drug.
2009 - 2010 Investigation of vascular smooth muscle proliferation by glucose fluctuation

Papers (52)：

Yuki Tanaka, Chikayo Iwaya, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa, Toru Shigeoka, Toshihiko Yanase, Daiji Kawanami, Takashi Nomiyama. Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetology international. 2022. 13. 3. 480-492
Leona Yamamoto, Shinichi Yamashita, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Toru Shigeoka, Tsuyoshi Horikawa, Yuki Tanaka, Toshihiko Yanase, Daiji Kawanami, et al. Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro. Diabetology international. 2021. 12. 4. 389-398
Tsuyoshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Yuki Tanaka, Shotaro Kita, Ryutaro Ryorin, Yuichi Takashi, Hiroyuki Takahashi, Makito Tanabe, Toshihiko Yanase, et al. Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet. Heliyon. 2020. 6. 11. e05431
Toru Shigeoka, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi, Tsuyoshi Horikawa, Tomoko Tanaka, Shinichiro Irie, Ryoko Motonaga, Nobuya Hamanoue, Makito Tanabe, et al. Activation of overexpressed glucagon-like peptide-1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression. Journal of diabetes investigation. 2020. 11. 5. 1137-1149
Yuichi Terawaki, Chikayo Iwaya, Takashi Nomiyama, Dai Shimono, Tsuyoshi Horikawa, Yuki Fujimura-Tanaka, Toru Shigeoka, Nobuya Hamanoue, Ryoko Motonaga, Makito Tanabe, et al. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F). Diabetology international. 2020. 11. 3. 274-282

ｍore...

MISC (28)：

野見山崇, 柳瀬敏彦. インスリン分泌促進薬の併用療法 : インクレチン関連薬+SU受容体作動薬 (特集インスリン分泌促進系薬). 糖尿病の最新治療. 2017. 9. 1. 20-25
野見山崇, 小松志保, 重岡徹, 野田智弘, 岩屋智加予, 堤陽子, 柳瀬敏彦. インクレチンと癌 : 糖尿病診療の新たな敵に立ち向かう. 日本体質医学会雑誌 = The Japanese journal of constitutional medicine. 2017. 79. 2. 88-94
柳瀬敏彦, 田邉真紀人, 野見山崇. テストステロン総論 (特集女性にとってのテストステロン). 最新女性医療 = Women's healthcare update : 女性医療の今を伝える専門誌. 2017. 4. 1. 6-11
小松志保, 野見山崇, 沼田朋大, 川波賢子, 濱口百合子, 高橋貴理子, 田中智子, 井上隆司, 柳瀬敏彦. SGLT2阻害薬イプラグリフロジンは乳癌細胞増殖を抑制する. 日本内分泌学会雑誌. 2017. 93. 1
野見山崇, 重岡徹, 小松志保, 柳瀬敏彦. インクレチンは悪性腫瘍を抑制できるか : beyond the blood glucose control (特集悪性腫瘍と糖代謝,インスリン作用). 尿酸と血糖 = Journal of uricemia & glycemic research. 2016. 2. 3. 138-141

ｍore...

Books (1)：

チャートでわかる糖尿病治療薬処方のトリセツ ~未来を護るベストチョイス~
南江堂 2017

Education (2)：

1998 - 2002 Juntendo University Graduate School, Division of Medical Science Diabetology
1988 - 1995 Juntendo University Faculty of Medicine Scchool of Medicine

Professional career (1)：

Diabetology (Juntendo University)

Awards (2)：

2006 - University of Kentucky Young Investigator Travel Award of 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology
2004 - Juntendo University Young Investigator Award of Japan Endocrinology Society

Association Membership(s) (5)：

日本糖尿病学会 , 日本内科学会 , 日本動脈硬化学会 , 日本体質医学会 , 日本スポーツ医学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page